​

Ionis Pharmaceuticals (IONS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IONS Stock Forecast

Ionis Pharmaceuticals (IONS) stock forecast, based on 33 Wall Street analysts, predicts a 12-month average price target of $87.00, with a high of $115.00 and a low of $54.00. This represents a 55.30% increase from the last price of $56.02.

$30 $47 $64 $81 $98 $115 High: $115 Avg: $87 Low: $54 Last Closed Price: $56.02

IONS Stock Rating

Ionis Pharmaceuticals stock's rating consensus is Buy, based on 33 Wall Street analysts. The breakdown includes 1 Strong Buy (3.03%), 18 Buy (54.55%), 14 Hold (42.42%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 33 14 18 1 Strong Sell Sell Hold Buy Strong Buy

IONS Price Target Upside V Benchmarks

TypeNameUpside
StockIonis Pharmaceuticals55.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts71942
Avg Price Target$75.57$86.84$91.88
Last Closing Price$56.02$56.02$56.02
Upside/Downside34.90%55.02%64.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 269105--24
Aug, 269103--22
Jul, 268124--24
Jun, 269125--26
May, 267116--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Barclays$85.00$56.7149.89%51.73%
Sep 08, 2026Tiago FauthRaymond James$84.00$56.4248.88%49.95%
Sep 08, 2026Michael UlzMorgan Stanley$104.00$56.7083.42%85.65%
Sep 08, 2026Canaccord Genuity$85.00$58.0946.32%51.73%
Sep 08, 2026BMO Capital$54.00$58.09-7.04%-3.61%
Sep 08, 2026Goldman Sachs$56.00$58.09-3.60%-0.04%
Sep 04, 2026David LebowitzBMO Capital$61.00$58.134.94%8.89%
Jul 30, 2026Mitchell KapoorH.C. Wainwright$115.00$54.04112.81%105.28%
Jul 29, 2026Goldman Sachs$69.00$54.0427.68%23.17%
Jul 21, 2026Debjit ChattopadhyayGuggenheim$89.00$52.9568.08%58.87%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 08, 2026Raymond JamesOutperformOutperformhold
Sep 08, 2026Morgan StanleyOverweightOverweighthold
Sep 08, 2026Cowen & Co.BuyBuyhold
Sep 08, 2026NeedhamBuyBuyhold
Sep 07, 2026CitigroupBuyBuyhold
Sep 04, 2026BMO CapitalMarket PerformMarket Performhold
Aug 31, 2026H.C. WainwrightBuyBuyhold
Aug 18, 2026BMO CapitalOutperformMarket Performinitialise
Jul 29, 2026Goldman SachsNeutralNeutralhold
Jul 23, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.20$-1.90$-2.56$-3.04$-2.38---
Avg Forecast$-1.45$-2.49$-3.28$-3.48$-3.70$-2.77$-1.10$0.74
High Forecast$-1.19$-1.93$-2.81$-3.22$-2.51$-1.37$0.63$1.00
Low Forecast$-1.98$-3.17$-3.55$-3.69$-4.63$-4.44$-2.51$0.51
Surprise %-86.21%-23.69%-21.95%-12.64%-35.68%---

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$810.46M$587.37M$787.65M$705.14M$944.00M---
Avg Forecast$650.76M$583.98M$637.10M$617.72M$670.75M$878.39M$1.26B$1.73B
High Forecast$835.45M$707.22M$677.83M$672.60M$746.22M$919.59M$1.30B$2.19B
Low Forecast$561.15M$482.28M$588.31M$595.85M$600.55M$837.19M$1.21B$1.32B
Surprise %24.54%0.58%23.63%14.15%40.74%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.60M$-269.72M$-366.29M$-453.90M$-381.00M---
Avg Forecast$390.43M$303.04M$-366.29M$-494.61M$-603.06M$-421.47M$-140.21M$105.64M
High Forecast$557.81M$471.95M$-133.57M$-461.54M$-358.99M$-196.70M$90.77M$142.72M
Low Forecast$223.04M$134.13M$-599.01M$-527.68M$-662.75M$-635.48M$-359.46M$73.45M
Surprise %-107.32%-189.01%--8.23%-36.82%---

IONS Forecast FAQ

Is Ionis Pharmaceuticals stock a buy?

Ionis Pharmaceuticals stock has a consensus rating of Buy, based on 33 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 18 Buy, 14 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ionis Pharmaceuticals is a favorable investment for most analysts.

What is Ionis Pharmaceuticals's price target?

Ionis Pharmaceuticals's price target, set by 33 Wall Street analysts, averages $87 over the next 12 months. The price target range spans from $54 at the low end to $115 at the high end, suggesting a potential 55.30% change from the previous closing price of $56.02.

How does Ionis Pharmaceuticals stock forecast compare to its benchmarks?

Ionis Pharmaceuticals's stock forecast shows a 55.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ionis Pharmaceuticals over the past three months?

  • September 2026: 37.50% Strong Buy, 41.67% Buy, 20.83% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 40.91% Strong Buy, 45.45% Buy, 13.64% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Ionis Pharmaceuticals’s EPS forecast?

Ionis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.77, marking a 16.39% increase from the reported $-2.38 in 2025. Estimates for the following years are $-1.1 in 2027, and $0.74 in 2028.

What is Ionis Pharmaceuticals’s revenue forecast?

Ionis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $878.39M, reflecting a -6.95% decrease from the reported $944M in 2025. The forecast for 2027 is $1.26B, and $1.73B for 2028.

What is Ionis Pharmaceuticals’s net income forecast?

Ionis Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-421M, representing an 10.62% increase from the reported $-381M in 2025. Projections indicate $-140M in 2027, and $105.64M in 2028.